{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:23:40Z","timestamp":1783527820371,"version":"3.55.0"},"reference-count":11,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Introduction: The anaplastic lymphoma kinase (ALK) fusion gene is expressed in 3%\u20135% patients with non-small cell lung cancer; targeting this gene with molecular targeted therapy results in a positive long-term prognosis. However, the ALK fusion gene expression rate is only 0.8% when restricted to pulmonary squamous cell carcinoma. Case Presentation: A 61-year-old non-smoking woman had undergone partial resection of the right lower lobe for lung adenocarcinoma 5 years previously, and ALK fusion gene positivity was confirmed at that time. Computed tomography (CT) revealed subcarinal lymph node enlargement. Subsequent positron emission tomography-CT imaging showed high uptake at this site and in the hepatic hilar lymph nodes. Subcarinal and hilar lymph node biopsies resulted in a diagnosis of squamous cell carcinoma. Squamous cell carcinoma of unknown primary was diagnosed because only metastatic lymph nodes were identified without a detectable primary lesion. Furthermore, the clinical presentation was considered inconsistent with metastatic recurrence, given the distinct histopathological difference from the initial surgical specimen and long disease-free interval. Treatment with carboplatin and paclitaxel was initiated. Although initial tumor reduction was achieved, the lesion subsequently progressed. After next-generation sequencing revealed ALK fusion gene positivity, the introduction of alectinib was effective. Conclusion: Alectinib is effective against ALK fusion gene-positive squamous cell carcinoma of unknown primary.<\/jats:p>","DOI":"10.1159\/000552510","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:00:49Z","timestamp":1783526449000},"page":"904-910","source":"Crossref","is-referenced-by-count":0,"title":["Primary Unknown Squamous Cell Carcinoma with the Anaplastic Lymphoma Kinase Fusion Gene That Was Effectively Treated with Alectinib: A Case Report"],"prefix":"10.1159","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2281-7778","authenticated-orcid":false,"given":"Keita","family":"Kawakado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tokumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoki","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2014.11.11"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28114"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30565-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.013"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(03)00547-1"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-12"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3468-1"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000521157"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28030180"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0439"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.01.001"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:00:50Z","timestamp":1783526450000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000552510","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.32260737","asserted-by":"subject"}]},"ISSN":["1662-6575"],"issn-type":[{"value":"1662-6575","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}